Baseline 11C-methionine PET reflects the natural course of grade 2 oligodendrogliomas
2005 (English)In: Neurological Research, ISSN 0161-6412, Vol. 27, no 5, 516-521 p.Article in journal (Refereed) Published
OBJECTIVES: The aim of the present study was to assess the usefulness of positron emission tomography (PET) with the amino acid tracer 11C-methionine (MET) as a predictor of time to progression (TTP) in patients with supratentorial grade 2 gliomas.
METHODS: Twenty-seven patients with glioma grade 2 subjected to a baseline PET scan received no anti-tumour treatment except for a diagnostic operation, and were followed until tumour progression. The prognostic impact of the MET uptake and of other prognostic factors was studied.
RESULTS: Twenty-five of the patients (93%) experienced tumour progression after a median of 103 weeks. Low uptake of MET was a predictor for long TTP in patients with oligodendrogliomas (p = 0.04) but not in astrocytomas/oligoastrocytomas. Other predictors for long TTP were oligodendroglioma histology (p = 0.009) and seizures as presenting symptom (p = 0.03). Favourable prognostic factors for overall survival were oligodendroglioma histology (p = 0.002) and good performance status (p = 0.03).
CONCLUSIONS: PET MET has a definite role in the therapeutic management of grade 2 gliomas. However, for the optimal use of PET MET in the clinical management of these patients, histological subclassification of the tumour is required.
Place, publisher, year, edition, pages
2005. Vol. 27, no 5, 516-521 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-219394DOI: 10.1179/174313213X13789811969265PubMedID: 15978178OAI: oai:DiVA.org:uu-219394DiVA: diva2:699659